Reference : A randomized double-blind placebo-controlled trial of thioctic acid in migraine proph...
Scientific journals : Article
Human health sciences : Neurology
http://hdl.handle.net/2268/4973
A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis
English
Magis, Delphine mailto [Centre Hospitalier Universitaire de Liège - CHU > > Neurologie Sart Tilman >]
Ambrosini, Anna [> > > >]
Sandor, Peter [> > > >]
Jacquy, Jean Jacquy [> > > >]
Laloux, Patrice [> > > >]
Schoenen, Jean mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Neuro-anatomie]
Jan-2007
Headache
Blackwell Publishing
47
1
52-57
Yes (verified by ORBi)
International
0017-8748
Oxford
[en] migraine prophylaxis ; mitochondria ; energy metabolism ; thioctic acid
[en] BACKGROUND: Impaired mitochondrial phosphorylation potential may play a role in migraine pathogenesis. Metabolic enhancers, such as riboflavin or coenzyme Q, are effective in migraine prophylaxis and quasi-devoid of adverse effects. Thioctic acid (-lipoic acid) is another substance known to enhance energy metabolism in mitochondria and to be beneficial in diabetic neuropathy. OBJECTIVE: After an open pilot study suggesting its therapeutic antimigraine potentials, we embarked therefore in a randomized controlled trial of thioctic acid (Thioctacid) in migraine prophylaxis steered by the Belgian Headache Society. METHODS: Five Belgian centers recruited 54 migraineurs (43 migraine without aura, 11 with aura; mean age 38 +/- 8 years; 7 males). After a 1-month single-blinded run-in period, 44 patients received either placebo (n = 18) or thioctic acid 600 mg p.o./day (n = 26) for 3 months. RESULTS: Statistical analysis was carried out on an intention-to-treat basis. Monthly attack frequency tended to be reduced between run-in and the 3rd month of treatment in the thioctic acid group compared to placebo (P= .06). The proportion of 50% responders was not significantly different between thioctic acid (30.8%) and placebo (27.8%). Within-group analyses showed a significant reduction of attack frequency (P= .005), headache days (P= .009), and headache severity (P= .03) in patients treated with thioctic acid for 3 months, while these outcome measures remained unchanged in the placebo group. No adverse effects were reported. For logistical reasons this trial was interrupted before the planned 80 patients were enrolled. CONCLUSION: Albeit underpowered, this study tends to indicate that thioctic acid may be beneficial in migraine prophylaxis. Before any firm conclusion can be drawn, however, a large multicenter trial is necessary.
Researchers ; Professionals
http://hdl.handle.net/2268/4973
10.1111/j.1526-4610.2006.00626.x

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
thioctic.pdfNo commentaryPublisher postprint99.69 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.